You are here

Phase III Program Evaluates Clostridium difficile Vaccine

Subjects recruited for large international trial (August 5)

A phase III clinical program called Cdiffense has been initiated to evaluate the safety, immunogenicity, and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI) (Sanofi Pasteur).

C. difficile is a potentially life-threatening, spore-forming bacterium that causes intestinal disease, which can lead to death in approximately 8% to 15% of infected people. The risk of CDI increases with age, antibiotic treatment, and the time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. Since 20% to 30% of patients experience recurrences of CDI, rehospitalizations and longer hospital stays remain common.

The investigational vaccine is designed to help protect at-risk individuals from C. difficile, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide. The vaccine produces an immune response that targets the toxins generated by C. difficile bacteria, which can cause inflammation of the gut and lead to diarrhea.

The Cdiffense phase III clinical program has started recruiting subjects for a randomized, observer-blinded, placebo-controlled trial that will include up to 15,000 adults at 200 sites in 17 countries.

Source: Sanofi Pasteur; August 5, 2013.

Recent Headlines

Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs